Drug Type Radiolabeled antibody, Diagnostic radiopharmaceuticals |
Synonyms CG250-IN111 |
Target |
Mechanism caspase inhibitors(Caspase inhibitors), SPECT(Single-photon emission-computed tomography enhancers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Kidney Neoplasms | Phase 2 | NL | 22 Mar 2017 | |
Renal Cell Carcinoma | Phase 2 | NL | 28 Feb 2005 |
Phase 1/2 | 26 | (Cohort 1, 30 mCi/m^2 177-Lu-DOTA-cG250) | nskwybaoot(kzpejvhmvn) = mwwlhkxhti fwiqelwyuo (oqfyotermv, rhalvlyvak - rgxwpzxkbl) View more | - | 22 Mar 2017 | ||
(Cohort 2, 40 mCi/m^2 177-Lu-DOTA-cG250) | nskwybaoot(kzpejvhmvn) = jcqekcehsi fwiqelwyuo (oqfyotermv, ncgcgdvamw - ecnkpexylz) View more |